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Abstract
Peptide transporters are present in all species to absorb the small peptides that occur ubiquitously as products of
proteolysis. The broad substrate specificities of these systems allow them to be exploited therapeutically for delivery of
peptidomimetic drugs in microbes and man. To this end, glycylsarcosine is currently used as a standard substrate for assaying
peptidomimetic transport by peptide transporters. However, in this study we find it is unsuitable as a general substrate, based
on assays of its transport by model bacterial peptide transporters and computer-based conformational analysis of its
structure. Of the two generic transporters for di- and tripeptides, exemplified by Dpp and Tpp in Escherichia coli, only Dpp
can transport glycylsarcosine. The explanation for this finding came from molecular modelling, which indicated that
glycylsarcosine can adopt only a restricted range of conformers compared with typical dipeptides, and that of the conformers
with a trans peptide bond, the majority have the specific psi (i) and phi (P) backbone torsion angles needed for molecular
recognition and transport by Dpp but none possessed i and P torsions required for recognition by Tpp; moreover, 38% of its
conformers have cis peptide bonds that are not substrates for any peptide transporter. Thus, using glycylsarcosine as
substrate in competition assays with compounds that typically form conformers recognised by both types of peptide
transporter will underestimate their transport. These findings have implications for assays of oral availability of
peptidomimetic drugs such as L-lactams, ACE inhibitors and anti-viral compounds, for which glycylsarcosine is routinely
used. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Peptide transporters exist in Nature to move the
small peptides that result from protein hydrolysis
across membranes but they also o¡er an attractive
route for delivery of therapeutic peptidomimetics
[1^8]. In microorganisms, peptide permeases mostly
absorb nutrient peptides produced in their extracel-
lular environment but, in addition, various organ-
isms synthesise antimicrobial peptide analogues that
gain access to their intracellular targets through these
permeases [1,2,5,7,8]. The analogous systems present
in the intestine are there to absorb the products of
protein digestion [1^4] but they can also be exploited
for oral uptake of a variety of drugs, e.g., to treat
hypertension, antiviral agents and L-lactam antibiot-
ics [6^8]. Similar systems occur in other animal tissues
and organs as well as in plants and insects [1,5,7].
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The peptide transporters that are best character-
ised at a molecular and biochemical level are those in
bacteria, exempli¢ed by the two archetypal perme-
ases for dipeptides and tripeptides (Dpp (SwissProt
P23847) and Tpp (SwissProt P77304)) and that for
tri- and higher oligopeptides (Opp (SwissProt P23843
and P76829)) [5,9]. To be able to explain their indi-
vidual substrate speci¢cities and to design com-
pounds optimised for absorption by one or other
transporter, it is necessary to understand the molec-
ular basis for their ability to recognise their natural
peptide substrates. This information is provided by
descriptions of the individual molecular recognition
templates (MRTs) for Dpp, Tpp and Opp [10^13].
The main features involved in de¢ning each MRT
are: (i) N-terminal K-amino and C-terminal K-car-
boxyl groups; (ii) backbone torsion angles i, P and
g ; (iii) chiral centres at K-carbons; (iv) N^C distance
between terminal amino and carboxylate groups;
(v) side chain torsion angles, M ; (vi) hydrogen-bond
donor and acceptor properties of peptide bond
atoms; and (vii) charge ¢elds around terminal amino
and carboxylate groups. For the model bacterial pep-
tide permeases, their MRTs were derived using cor-
relations between the results of conformational anal-
yses on a range of di-, tri-, and oligopeptides and
measurements of their binding and transport by
each permease [10^13]. Although several of these fea-
tures are shared by all peptide conformers, variations
in i and P are critical determinants of the individual
speci¢cities of each peptide transporter. For example,
Dpp-type peptide transporters recognise conformers
with i of +140‡ to 3175‡ whereas Tpp-type peptide
transporters are speci¢c for i of 350‡ to 385‡ or
+50‡ to +85‡; both types of transporter recognise
conformers with P of 350‡ to 395‡ or 3130‡ to
+175‡. These particular backbone conformations im-
pose speci¢c geometries on the charged N-terminal
amino and C-terminal carboxylate groups, which are
important for ligand binding [10^12]. De¢nition of
the MRTs for these three peptide transporters
showed that they complement each other in their
substrate speci¢cities, in that each recognises sepa-
rate, speci¢c classes of peptide conformers so that
acting together they maximise absorption of all small
peptides [10^13]. Thus, the speci¢cities of these ge-
neric peptide transporters have evolved interactively,
driven by the selective pressure of the typical reper-
toire of peptide conformers that arise wherever pro-
teins are hydrolysed. Their substrate speci¢cities are
independent of the protein architecture of the trans-
porter, which may comprise a single, membrane-
bound, multi-domain protein energised by a proton
motive force, e.g., Tpp or a multi-protein, membrane
assembly with a separate protein for peptide recog-
nition and binding, e.g., as with Dpp [14].
Because substrates must adopt appropriate back-
bone conformations to be recognised by one or other
peptide transporter, one can evaluate whether or not
a compound is a potential substrate for a particular
peptide transporter by consideration of the conform-
ers it forms in solution, which can be evaluated by
conformational analysis. Amongst the many peptide
analogues that have been tested for transport, pep-
tides with N-methylated peptide bonds, e.g., glycyl-
sarcosine (GSar; G-N-methyl-G), have been shown
to be transported by animal, plant and microbial
systems, although in all these systems GSar is trans-
ported markedly less well than any normal dipeptide
[1,2,5,15,16]. Because these analogues such as GSar
are also particularly resistant to hydrolysis by pepti-
dases they can be accumulated intact, overcoming
the problem of extensive cleavage commonly seen
with normal peptide substrates. Consequently, when
such cleavage is a problem, e.g., with intestinal villi,
GSar has become the prototypic substrate used in
competition assays to evaluate transport of peptido-
mimetic drugs by intestinal, renal and other peptide
transporters [2,4,7,8,17,18].
In this paper, we have examined GSar for its suit-
ability as a standard substrate for use in such trans-
port assays. Conformational analysis shows that it
adopts a limited range of conformers that restrict it
to being a substrate for Dpp-type transporters and
not for Tpp-type transporters. This theoretical pre-
diction was corroborated by transport assays with
speci¢c peptide permease mutants of Escherichia
coli and peptide binding studies, which showed
GSar to be transported by Dpp but not by Tpp.
These ¢ndings may compromise the use of GSar
for assessing absorption of peptidomimetic com-
pounds, particularly for compounds that exist mainly
in conformations recognisable by a Tpp-type rather
than a Dpp-type transporter.
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2. Materials and methods
2.1. Conformational analysis of peptides
Peptides were modelled in their zwitterionic form
using a random search procedure in which all tor-
sions were allowed to vary; SYBYL 6.5 software
(Tripos, St Louis, MO) running on a Silicon
Graphics Octane workstation was used, essentially
as described [10^13]. The computed conformers for
each peptide were ranked according to energy, and
by comparing the energy of each with that of the
minimum energy conformer, the percentage of each
form was calculated using a Boltzmann distribution.
For each conformer, its i, P and g torsion angles
were measured, together with other relevant features
such as N^C distance [10^13]. For each compound,
i and P torsional space for the e¡ective peptide unit
was divided into 36 10‡ sectors and for all conform-
ers with particular i^P combinations their individual
percentages were aggregated. The collection of con-
formers for any compound could then be displayed
using a three-dimensional pseudo-Ramachandran
(3DPR) plot that relates percentage of conformer
to its i and P angles. This plot conveniently shows
the extent to which the conformer pro¢le of any
compound matches the torsional requirements of
the MRT for each peptide transporter [10^13].
Energy pro¢les for peptides were calculated using
grid search conformational analysis, with g main-
tained at þ 180‡ and P at 375‡ and with i allowed
to vary from 3170‡ to þ 180‡ in 10‡ increments.
2.2. Assays of peptide transport and binding
Transport studies were carried out using E. coli K-
12 peptide permease mutants described previously
[9] : strain PA0410 (opp, tpp), which has only a func-
tional Dpp, and strain PA0333 (opp, dpp), which has
only an active Tpp. Transport of [14C]GSar by
strains PA0333 and PA0410 was measured essentially
as described [9]. With this substrate, which is pepti-
dase resistant, the amino acid e¥ux seen with normal
peptides is not a problem for transport assays [5].
Brie£y, exponential-phase bacteria (10 ml 109 cells
ml31) were incubated with GSar (0.1 mM) in 50
mM phosphate bu¡er (pH 7.2) with 0.2% (w/v) D-
glucose, 1 ml samples were removed periodically over
about 12 min, ¢ltered through glass-¢bre mem-
branes, and washed twice with 5 ml phosphate-bu¡-
ered saline before drying and counting for retained
radioactivity. Controls were performed without cells
or GSar. In addition, GSar transport was assayed
£uorimetrically, as was the transport of other dipep-
tides, as described previously [9].
Binding of [14C]GSar (speci¢c radioactivity 56.8
mCi mmol31) (Cambridge Bioscience) and [14C]GL
(speci¢c radioactivity 20 mCi mmol31) (Amersham)
to dipeptide-binding protein (DppA) was carried out
as described previously [9]. Brie£y, samples of puri-
¢ed DppA (20 WM, 29 Wg) freed from endogenous
ligands were incubated with varied amounts of
[14C]GL (25 Wl, 1^600 WM) or GSar (25 Wl, 50 WM^
1 mM) at 37‡C for 30 min, before addition of 0.9 ml
ice-cold, saturated ammonium sulphate solution;
samples were ¢ltered using polycarbonate mem-
branes in a Millipore manifold and washed three
times with 2.0 ml of the ammonium sulphate solution
before counting for retained radioactivity. Controls
were carried out in which DppA or ligand were omit-
ted.
3. Results
3.1. Conformational analysis of dipeptides
In previous studies, a random search method has
been shown to be optimal to determine the repertoire
of conformational forms adopted by charged dipep-
tides in water [10^13]. This approach was used here
to analyse GSar; for comparison, modelling was
done of the analogues GG and GP, the latter often
being used as an alternative substrate to GSar, and
of the standard dipeptide AA. For each peptide, sep-
arate random searches of 1k and 5k iterations were
performed and results were combined; the total
number of unique conformers found for GSar, GP,
GG and AA were 37, 15, 55 and 18, respectively. The
energies, torsional values and N^C distances for the
twelve main conformers of each peptide are shown in
Table 1. For GSar and GP, only those conformers
with i angles of about +160‡ to 3175‡ match the
requirements of an MRT, whereas all conformers of
AA and to a lesser extent those of GG match well
[10^12]. Minimum energy conformers of GSar and
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Table 1
Conformational parameters for main conformers of AA, GG, GP and GSar
Conformer Energy (kcal mol31) Boltzmann Percent i g P N^C (Aî )
AA1 2.40 1.00 22.52 165.0 178.4 365.1 5.300
AA2 2.57 0.76 17.12 165.4 3179.1 3159.1 6.122
AA3 2.67 0.65 14.57 164.3 178.6 51.3 5.056
AA4 3.02 0.37 8.29 73.1 179.6 365.6 5.332
AA5 3.03 0.36 8.11 73.7 3178.0 3159.8 5.410
AA6 3.08 0.33 7.50 362.6 178.9 366.0 4.656
AA7 3.15 0.29 6.66 361.5 3178.5 3159.2 5.119
AA8 3.19 0.28 6.22 73.3 179.8 51.4 4.683
AA9 3.37 0.21 4.69 362.5 179.3 51.4 5.277
AA10 3.67 0.13 2.87 363.0 178.4 382.5 4.647
AA11 4.39 0.04 0.89 147.8 32.7 374.2 4.339
AA12 4.99 0.01 0.33 104.4 0.6 361.3 3.355
GG 1 2.61 1.00 12.40 3179.3 179.3 365.1 5.247
GG 2 2.61 1.00 12.40 179.3 3179.4 65.1 5.248
GG 3 2.71 0.85 10.61 378.5 178.5 366.1 4.637
GG 4 2.71 0.85 10.62 78.5 3178.5 66.1 4.636
GG 5 2.83 0.70 8.75 78.1 179.8 365.2 5.366
GG 6 2.83 0.70 8.75 377.9 3179.8 65.4 5.365
GG 7 2.93 0.60 7.41 179.9 þ 180 179.9 6.166
GG 8 3.07 0.47 5.85 77.8 3179.6 179.4 5.384
GG 9 3.07 0.47 5.85 377.8 179.6 3179.3 5.383
GG 10 3.28 0.34 4.20 377.7 179.6 3179.3 5.367
GG 11 3.51 0.23 2.89 172.1 31.5 375.9 4.612
GG 12 3.51 0.23 2.89 3172.1 1.5 75.9 4.613
GP 1 9.03 1.00 21.09 171.7 30.3 378.6 4.644
GP 2 9.06 0.94 20.05 171.2 3179.7 375.7 5.413
GP 3 9.40 0.55 11.64 3168.9 178.7 351.9 5.112
GP 4 9.64 0.37 7.92 3161.0 31.3 355.0 4.463
GP 5 9.66 0.36 7.58 394.6 179.8 375.6 4.770
GP 6 9.70 0.34 7.11 395.0 30.2 378.3 4.382
GP 7 9.70 0.33 7.07 173.3 þ 180.0 376.5 5.399
GP 8 9.91 0.24 5.09 103.8 2.8 370.0 3.464
GP 9 10.00 0.21 4.38 105.2 31.7 356.1 3.332
GP 10 10.14 0.16 3.47 95.6 178.7 351.8 5.389
GP 11 10.34 0.12 2.51 91.2 3176.4 380.8 5.540
GP 12 10.75 0.06 1.30 388.0 175.1 348.4 4.693
GSar 1 4.39 1.00 14.80 3168.9 0.0 80.6 4.623
GSar 2 4.39 1.00 14.80 168.9 0.0 380.7 4.623
GSar 3 4.47 0.88 12.91 173.0 3178.6 69.7 5.168
GSar 4 4.47 0.88 12.91 3173.1 178.6 369.7 5.169
GSar 5 4.60 0.71 10.44 3170.3 þ 180.0 88.2 5.514
GSar 6 5.22 0.26 3.80 396.9 þ 180.0 373.9 4.736
GSar 7 5.27 0.24 3.49 395.8 0.3 378.9 4.376
GSar 8 5.27 0.24 3.49 95.8 30.3 78.9 4.376
GSar 9 5.37 0.20 2.97 3106.1 30.4 62.2 3.350
GSar 10 5.37 0.20 2.97 106.0 0.4 362.3 3.350
GSar 11 5.39 0.20 2.91 95.2 178.8 368.9 5.432
GSar 12 5.40 0.19 2.85 97.4 3179.8 87.9 4.820
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GP have cis peptide bonds and correspondingly
shorter N^C distances. Because only peptides having
trans peptide bonds can be recognised and trans-
ported by peptide transporters [1,2,5,9^13,19,20], cis
conformers need ¢rst to be removed from consider-
ation as putative substrates. The total amounts of
conformers computed to exist with cis peptide bonds
for GSar, GP, GG and AA were 38%, 46%, 14% and
1%, respectively.
Using only the collection of trans conformers for
each peptide, the percentage of each conformer was
plotted against its i and P angles to produce a 3DPR
Fig. 1. Three-dimensional pseudo-Ramachandran plots of dipeptides. (a) Alanylalanine, AA; (b) glycylglycine, GG; (c) glycylproline,
GP; (d) glycylsarcosine, GSar. For each compound, the percentage of each conformer (excluding those with cis peptide bonds) is plot-
ted against its i (A1^A12) and P (B1^B12) torsions. Conformers recognised by Dpp-type DT(A7) transporters have A7B9 and A7B12
torsions and those recognised by Tpp-type DT(A4,10) transporters have A4(B9+B12) and A10(B9+B12) torsions; precise values for
these torsional angles are given in the text.
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plot (Fig. 1). The plots for these peptides share many
features found for all dipeptides [10^13] but each
shows unique characteristics. AA is a model dipep-
tide [9^13] and its i and P torsions are typical of
most dipeptides (Fig. 1a): i torsions are in the
ranges +145‡ to +175‡, 370‡ to 385‡ and +65‡ to
+85‡, referred to as A7, A4 and A10, respectively,
and its P torsions occur in the ranges 360‡ to 370‡,
3145‡ to 3170‡ and +50‡ to +60‡, referred to as B9,
B12 and B2, respectively [10^13]. Determination of
the molecular recognition parameters for bacterial
peptide transporters has established that substrates
of Dpp-type transporters must possess A7 i tor-
sions, whereas Tpp-type transporters are speci¢c for
A4 and A10 torsions; both recognise B9 and B12
P torsions but neither can recognise B2 forms [10^
13]. With GG, its main conformational forms occupy
related ranges to those for AA but the greater back-
bone rotation uniquely allowed with the small side
chains of G results in a much wider spread of i and
P angles (Fig. 1b). Its A7, A4 and A10 i torsions fall
approximately within the ranges +140‡ to 3175‡,
350‡ to 385‡ and +50‡ to +85‡, respectively, and
its B9, B12 and B2, P torsions occur approximately
in ranges 350‡ to 395‡, 3130‡ to +175‡ and +40‡ to
+85‡, respectively; these deviations from optimal tor-
sions help to explain why it is one of the poorest
natural dipeptide substrates for all peptide transport-
ers [1,2,5,9^12]. GP adopts a much more limited
range of conformers, with acceptable i torsions
being restricted to A7 and others falling outside rec-
ognisable A4 and A10 ranges, with P torsions being
con¢ned to B9 sectors (Fig. 1c). GSar also adopts a
restricted conformational range (Fig. 1d). However,
whereas its A7 torsions are those of a typical dipep-
tide its other very minor conformers fall outside the
range of recognisable A4 and A10 sectors found in
any typical dipeptides [10^12]. The percentages of the
trans conformers that exist in the recognisable ranges
of i and P for these four dipeptides are summarised
in Table 2. These results indicate that the conforma-
tional forms of GSar and GP appear to restrict these
dipeptides to being substrates for Dpp-type but not
for Tpp-type peptide transporters [10^12].
The reasons why AA and similar dipeptides adopt
Fig. 2. Energy pro¢les for AA and GSar computed using grid
search. g ( þ 180‡) and P (375‡) torsions were kept constant
whilst i angles were systematically varied by 10‡. Individual en-
ergy contributions to the total energy of each conformer were
calculated and plotted for AA (a) and GSar (b); total energy
(b) ; van der Waals energy (a) ; angle bending energy (P) ; elec-
trostatic energy (S).
Table 2
Percentages of main conformational forms of AA, GG, GP and GSar recognised by peptide transporters
Peptide A7 conformers A4 conformers A10 conformers
B9 B12 B2 B9 B12 B2 B9 B12 B2
AA 22.5 17.1 14.6 10.4 6.7 4.7 8.3 8.1 6.2
GG 10.3 12.3 10.3 8.8 4.9 11.9 11.9 4.9 8.8
GP 26.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
GSar 9.4 0.0 8.9 0.0 0.1 0.3 0.3 0.0 0.4
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a particular range of conformers [12], whereas GSar
(and GP) with a modi¢ed peptide bond adopts a
more restricted range, becomes clear from consider-
ation of the factors that contribute to the overall
energies of the conformers (Fig. 2). Grid searches
were carried out in which i angles were systemati-
cally varied by 10‡ over the whole of torsional space
whilst g was ¢xed in a trans bond ( þ 180‡) and P
(375‡) was kept constant in a B9 torsion. For AA
the main determinant of its energy pro¢le is van der
Waals energy whereas, unusually, with GSar angle
bending is the main contributor, making putative
A4 and A10 conformers unstable, high energy forms
(Fig. 2).
3.2. Transport of GSar by peptide transporters
Transport of [14C]GSar was measured using mu-
tants of E. coli in which only speci¢c peptide trans-
porters were functional [9]. Results for transport by
strain PA0410 (opp, tpp), which has only a functional
Dpp, and for strain PA0333 (opp, dpp), which has
only an active Tpp, are shown in Fig. 3. The initial
rate of [14C]GSar transport by Dpp was 3.4 nmol
min31 mg bacterial protein31, whereas transport by
Tpp was not detectable even at concentrations up to
10 mM (results not shown). Transport of unlabelled
GSar by the two strains was also measured using a
£uorescence assay; transport by Dpp was 3.5 nmol
min31 mg bacterial protein31 and zero by Tpp. Nat-
ural dipeptides derived from proteins exist typically
with the majority of their conformers shared between
the speci¢c forms recognised as substrates by Dpp
and Tpp [5,9^12] giving similar rates of uptake by
each, e.g., for AA, 28.5, 23.5; GF, 24.3, 14.5; GY,
33.1, 17.4; LW, 35.0, 14.4; and SA, 34.6, 27.1 for
Dpp and Tpp, respectively. The ratio of these rates is
typically in the range 1.2^2.4; in contrast, for GSar
the zero rate of uptake by Tpp makes this ratio in-
¢nity.
3.3. Binding of GSar to dipeptide binding protein
The dipeptide binding protein, DppA, is responsi-
ble for the initial recognition of substrates by Dpp
and there is a close correlation between binding of
compounds to DppA, measured using puri¢ed pro-
tein in vitro, and their transport through Dpp [5,9^
11]. Therefore, this provides an alternative technique
to evaluate the bioactivity of the conformer reper-
toire of GSar. Fig. 4 shows the binding curve for
[14C]GSar with DppA, together with that for
[14C]GL as a model substrate. Binding constants
were estimated to be about 0.6 mM and 0.2 mM
for GSar and GL, respectively. GL has been used
as a model substrate in the X-ray structure determi-
nation of a liganded-DppA complex, in which GL
adopted an A7B9 conformation [21], in accord with
the predictions based on molecular modelling [10^
12].
Fig. 3. Transport of glycylsarcosine by speci¢c peptide trans-
porters in Escherichia coli. Strain PA0410 (opp, tpp) has only a
functional Dpp system (b) and strain PA0333 (opp, dpp) has
only a functional Tpp system (R).
Fig. 4. Binding of dipeptides to peptide binding protein DppA.
Curves shown are for two separate binding experiments for gly-
cylleucine (b,a) and glycylsarcosine (R,O).
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4. Discussion
4.1. Common structural speci¢cities of peptide
transporters
Transporters for components of the peptide pools
that result from protein hydrolysis are ubiquitous in
Nature, being found in microorganisms, higher and
lower plants, insects and animal tissues and organs
[1]. Similar substrate speci¢city features are observed
for all these transporters, which may otherwise di¡er
in their complement of proteins, or their modes of
energisation or regulation [1^8]. Detailed descrip-
tions of the molecular recognition properties for in-
dividual peptide transporters [1^9,22^25] are compat-
ible with these speci¢cities having evolved similarly
in response to the structures of the same natural
substrates in the peptide pool [10^12].
4.2. Bacterial peptide transporters speci¢c for
dipeptides and tripeptides
In bacteria, molecular genetic techniques have es-
tablished the existence of two main permeases with
speci¢city only for di- and tripeptides, i.e., Dpp- and
Tpp-type transporters [1,5,9,14]. Extensive studies
have established detailed substrate speci¢cities for
these transporters [5,9] and these have been explained
in terms of the speci¢c structural conformers adopted
by di- and tripeptides in solution [10^12]. From cor-
relating these structure-activity relationships, the in-
dividual MRTs for a Dpp- and a Tpp-type trans-
porter have been de¢ned with respect to the
backbone torsions, side-chain orientations, N^C dis-
tances, etc., of a peptide substrate, and the two trans-
porters found to be complementary in recognising
di¡erent conformational forms of a peptide [10^12].
Similar MRTs are likely to have evolved for di- and
tripeptide transporters in all organisms in response to
the common selective pressure provided by the con-
former classes found in these peptides [11].
4.3. Classi¢cation of peptide transporters
Peptide transporters can be classi¢ed by various
criteria, and this becomes an important feature
when making comparisons between transporters in
various organisms. Thus, gene sequences, energy
coupling mechanisms, protein number/architecture
and substrate speci¢cities can each be used for cate-
gorisation but these di¡erent criteria may cut across
classi¢cation schemes. A classi¢cation based upon
gene sequencing gave ¢ve categories [14] : one class
being primary transporters (direct use of chemical
energy) in the ATP-binding cassette (ABC) super-
family, the other four being secondary transporters
driven by a proton gradient. ABC transporters in
prokaryotic and eukaryotic microorganisms, e.g.,
Dpp and Opp, comprise ¢ve proteins: one (DppA,
OppA) being a recognition/binding protein, which
may be free as in E. coli or membrane-bound as in
Bacillus subtilis, the other four proteins forming a
membrane-bound complex. Analogous mammalian
ABC transporters have all ¢ve proteins fused togeth-
er, with the substrate recognition domains being part
of the membrane-bound complex [26]. Secondary
transporters are members of the proton-dependent
oligopeptide transporter (POT) or peptide transport
(PTR) family that comprise single proteins typically
containing 12 transmembrane domains [14,27,28].
Bacterial Tpp and mammalian PepT1and PepT2 be-
long to this class [8,9,14,29]. Thus, these ABC and
POT transporters have entirely di¡erent protein ar-
chitectures yet all can transport common peptide
substrates. Furthermore, other hybrid transporters
have been characterised that are composed of combi-
nations of distinct functional modules of both sec-
ondary and ABC transporters, indicating that during
evolution the combination of integral membrane
transport proteins with either a cytosolic ATPase
or recognition/binding protein, or both, has resulted
in distinct types of transporters [30]. Consequently,
gene motifs, protein architecture or energy coupling
mechanisms may be permutated in various ways and
classifying a peptide transporter as one type or an-
other by these criteria does not necessarily allow ex-
trapolation to de¢nitive conclusions regarding their
precise substrate speci¢cities. Classi¢cation based on
substrate speci¢city requires results from biochemical
assays of transport and binding together with in-
sights into conformer pro¢les of substrates [9^13],
as illustrated by the studies here. However, there is
presently no classi¢cation scheme based on substrate
speci¢city, which makes it potentially confusing to
compare substrate speci¢cities of, e.g., Dpp (or
DppA) with PepT1, for their terminologies often de-
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rive from other classi¢cations. Thus, using ‘Dpp-
type’ and ‘Tpp-type’ when referring to transporter
speci¢cities as we have here, can unfortunately carry
connotations of gene sequences, protein architecture
and energy coupling. Consequently, we propose a
classi¢cation for peptide transporters based on their
substrate speci¢cities that includes the length of pep-
tide and the (pseudo) i torsional angle(s) of their
substrate conformers, which allows their substrate
speci¢cities to be compared irrespective of their clas-
si¢cations by other criteria. Thus, by this scheme, the
substrate speci¢city of Dpp and DppA is termed
DT(A7) (recognising Dipeptides and Tripeptides
with i of A7 (+140‡ to 3175‡)) and Tpp becomes
DT(A4,10) (recognising Dipeptides and Tripeptides
with i of A4 and A10 (350‡ to 385‡ or +50‡ to
+85‡)). As a further extension to these arguments, it
is well accepted that transporters for various amino
acids may be ABC systems and/or proton-linked sys-
tems in microorganisms whilst with the same sub-
strate speci¢cities they may be proton- or sodium-
linked secondary transporters in mammalian cells,
and, in addition, that many peptidases and proteases
can also be conveniently classi¢ed in terms of their
substrate speci¢cities although their protein architec-
tures and catalytic mechanisms may often be mark-
edly di¡erent [31].
4.4. GSar as a substrate of peptide transporters
The broad speci¢city pro¢le of peptide transport-
ers allows them to recognise peptides with certain
structural modi¢cations. For example, peptides with
N-methylated peptide bonds are substrates, albeit
relatively poor ones, for peptide transporters in mi-
croorganisms, plants, intestine and kidney [1^10].
The marked resistance of such peptides to peptidase
action has led to the adoption of GSar as a standard
substrate, particularly for studies with many mam-
malian tissues in which natural peptides are exten-
sively hydrolysed [2^4,6,8]. In such studies, radioac-
tively-labelled GSar acts as substrate with transport
of other compounds being assessed from their ability
to inhibit GSar uptake [6^8,17,18,25]. GP shows
analogous resistance to peptidases and it is often
used to complement studies with GSar [7,8,17,18].
Consequently, GSar, and to a lesser extent GP,
have been adopted as prototypic substrates for stud-
ies on oral drug availability. The presumption in
their use is that the ability of a therapeutic com-
pound to inhibit their uptake is generally an accurate
measure of the compound’s own ability to be ab-
sorbed by the various peptide transporters present,
except for the few compounds that may bind and
compete without actually being transported them-
selves [8].
4.5. Computer modelling of peptide substrates
A molecular modelling approach has been adopted
in several attempts to de¢ne the structural features
needed for substrate recognition by mammalian pep-
tide transporters using a range of natural substrates
and analogues that exploit peptide transporters, e.g.,
dipeptides, L-lactams and other drugs [7,22^25]. In
the more recent studies, important structural param-
eters have been identi¢ed that are in broad agree-
ment with results for bacterial peptide transporters
derived from modelling natural peptide substrates
[10^13]. Given these corroborations between theoret-
ical modelling and empirical, structure^activity rela-
tionships, we have here analysed GSar and GP to
assess their suitability as model substrates for peptide
transporters, whether it be for studies on antimicro-
bial peptidomimetics or for oral drug delivery. Mod-
elling showed that GSar and GP exist with 38% and
46%, respectively, of their conformers with cis pep-
tide bonds (Tables 1 and 2). These theoretical values
agree well with published experimentally values:
GSar 39 þ 1% and GP 48 þ 2% [19,20], endorsing
the general validity of the computed repertoire of
conformers for these compounds. Brandsch and co-
workers demonstrated that PepT1 could only trans-
port peptides with trans peptide bonds [19,20] and
the same conclusion was reached previously for mi-
crobial transporters from consideration of MRTs,
which showed that peptides with cis peptide bonds
fail to match several, critical structural parameters
[5,9^13]. Consequently, here we evaluated only those
conformers with trans peptide bonds as putative sub-
strates and these were displayed as 3DPR plots (Fig.
1). Conformers of GSar and GP exist only with A7
i torsions, which when combined with B9 P torsions
restrict them to being substrates exclusively for
DT(A7) (e.g., Dpp) transporters [10^12]. This expec-
tation was endorsed by results showing that in E. coli
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GSar could only be transported by a strain with a
functional Dpp system, no transport being detectable
by Tpp (Fig. 2). Similarly, GSar and GP have pre-
viously been shown to compete for uptake of dipep-
tides by Dpp but not by Tpp ([9^11]; unpublished
results). Typically, natural dipeptides are transported
through both systems [5,9^12]. A strong correlation
exists between transport of a compound by Dpp and
its binding to DppA, the recognition protein for Dpp
[5,9^12]. Here, GSar was shown to bind to DppA
but relatively poorly compared with GL and more
typical dipeptides [9^12], re£ecting its lowered con-
tent of trans forms and departure from the ideal
parameters for molecular recognition by DppA.
4.6. Number of intestinal peptide transporters
Early studies on intestinal peptide transport ad-
dressed the question of the number of di¡erent pep-
tide transporters present and Matthews, in a schol-
arly overview of the area [2], concluded that
‘‘...though a very large number of di- and tripeptides
of dissimilar structure do compete for intestinal
transport there are in fact at least two peptide trans-
port systems in the small intestine’’, and in this con-
text he cited the lack of reciprocal inhibition (when
extrapolated to in¢nite concentrations) between
GSar and other dipeptides such as AA, LL and
VV. More recently, the accumulated evidence for
the existence of several peptide transporters has
been reviewed [8,14], including use of techniques
for cloning and identi¢cation of peptide transporter
genes and proteins and extensive substrate speci¢city
studies aimed at de¢ning the number and nature of
peptide transporters involved in oral absorption of
peptidomimetic drugs. Fei and colleagues [29] identi-
¢ed the intestinal transporter PepT1 using an expres-
sion cloning strategy with Xenopus laevis oocytes and
screening an intestinal cDNA library for uptake of
[14C]GSar: using a hybrid-depletion experiment, they
also concluded that PepT1 was the only peptide
transporter for GSar in enterocytes, although in
such experiments variations in the timing and condi-
tions for mRNA expression do not rule out the oc-
currence of other peptide transporters [8]. However,
their conclusion that PepT1 is the only transporter
that can recognise GSar [8,24] would accord with
GSar modelling reported here. Furthermore, the
fact that PepT1, and the analogous renal transporter
PepT2 [8,14], both recognise GSar (and GP), which
can only exist as A7 conformers, is prima facie evi-
dence for consideration of their classi¢cation as
DT(A7) transporters.
The question remains as to the number of di-,
tripeptide transporters present in the intestine, kid-
ney (and other organs). Results from competitive
transport assays and other studies point strongly to-
wards there being more than one [1,2,8], and analo-
gous studies in other organisms would support this
expectation. If any unidenti¢ed transporter is a
DT(A4,10) type then its identi¢cation will require
use of a substrate(s) that adopts appropriate con-
formers with A4 and/or A10 i torsions.
4.7. Implications of GSar structure for assays of
peptide transport
The results reported here imply that the use of
GSar (and/or GP) as substrates in competition assays
to assess transport of competitor compounds will be
liable to error depending upon the conformer pro¢le
of the competitor. For a compound that exists exclu-
sively with the torsional forms A7(B9,B12) that
match DT(A7) transporters, e.g., bacterial Dpp,
and potentially PepT1 and PepT2, correlation be-
tween competitive ability and transport should be
good. In contrast, if a compound exists with a sig-
ni¢cant proportion of its conformers in other tor-
sional forms such as A4,A10(B9,B12) that are recog-
nised by a DT(A4,10) transporter, then correlation
will be poor with uptake being underestimated. This
conclusion could have signi¢cant implications for
current procedures to assess oral absorption of ther-
apeutic peptidomimetics by intestinal and renal pep-
tide transporters. Support for this has come not only
from modelling natural peptides but also a range of
orally active ACE inhibitors and L-lactam antibiot-
ics, which showed them to exist with not only A7 but
also with A4 and A10 torsional forms (unpublished
results). Further support for the suggestion that Dpp
and PepT1 may possess similar DT(A7) substrate
speci¢cities has come from the ¢nding that a range
of peptidomimetic ACE inhibitors, e.g., enalapril,
enaliprilat, lisinopril, etc., bind to DppA and that
their relative binding a⁄nities show a similar ranking
to that found for their abilities to compete for uptake
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of substrates by PepT1 (unpublished results). It still
remains to be determined whether any additional in-
testinal peptide transporter(s) possesses the comple-
mentary DT(A4,10) speci¢city; however, arguing tel-
eologically it would appear likely for that would
enhance absorption of the extensive component of
peptides produced by protein breakdown in the gut
that will exist in conformational forms recognised
exclusively by such transporters [10^13]. If peptide
transporters in di¡erent organisms have not evolved
common speci¢cities in response to similar selection
pressures, i.e., conformer pro¢les of their natural
peptide substrates, the question arises as to what
has provided the driving force for their speci¢cities;
looking for answers in the structures of poorly trans-
ported, synthetic mimetics that can exploit these sys-
tems does not seem to o¡er the best approach.
The present results highlight the advantages of
multi-disciplinary studies of related biological sys-
tems across various organisms, exempli¢ed here by
ubiquitous membrane transporters that have evolved
similar speci¢cities to optimise molecular recognition
of common substrates. Our current studies with sub-
strates for peptidases and proteases (unpublished re-
sults) indicate that the bene¢ts of such an approach
will not be limited to the rational design of therapeu-
tic agents tailored for delivery by peptide transport-
ers.
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